KOSDAQBiotech & Pharma491000

LivsMed

₩35,900▲ 11.15%2026-11-18 close
Market Cap
₩906.7B
Turnover
₩13.2B
Volume
370K
Shares out.
25.3M
PER
—
PBR
5.6×
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

LivsMed: Revenue Up, Losses Still Persist

LivsMed's revenue rose 88.8% in 2025, yet operating losses have continued for three consecutive quarters through the third quarter of 2026, so the timing of a profitability turn and the surgical robot approval are the key points to watch.

  1. 1

    Revenue reached KRW 51.2 billion in 2025, up 88.8% from the prior year, with domestic sales driving the growth.

  2. 2

    The operating loss narrowed to KRW 22.6 billion in 2025 from KRW 26.5 billion in 2024, and the operating margin improved from -97.7% to -44.2%.

  3. 3

    Third-quarter 2026 revenue was KRW 8.92 billion, down 28.7% from the prior quarter, with an operating loss of KRW 10.4 billion; the company attributed part of the decline to inventory adjustments during a product transition.

  4. 4

    Cash fell 50.9% by the end of June 2026 from year-end 2025, and the company signed loan agreements with Woori Bank and Hana Bank totaling KRW 28.4 billion.

  5. 5

    The STARK surgical robot entered the MFDS product approval application on August 7, 2026, and the new Yongin plant is planned to start operations in the second half of 2027.

02

Business structure

LivsMed is a medical device company whose core product is the ArtiSential multi-joint laparoscopic surgical instrument, which bends 90 degrees. Of 2025 consolidated revenue of KRW 51.2 billion, domestic sales were KRW 45.7 billion, up 94.9% from the prior year, and overseas sales were KRW 5.5 billion, up 49.3%.

Sales at overseas subsidiaries reached KRW 4.4 billion, growing 52.8%. The company says it has signed supply contracts with 72 countries and supplies products in 46 of them.

The number of hospitals using ArtiSential rose from 143 in the third quarter of 2023 to 262 at the end of the third quarter of 2026, and the number of surgeons using it rose from 315 to 695.

The product line is widening with the mass production of the high-grade ArtiSeal instrument, the ArtiStapler surgical stapler and the LivsCam laparoscopic camera. The core growth pillar is the STARK surgical robot, for which the company applied for MFDS product approval on August 7, 2026.

The company promotes an operating room platform strategy that links surgical instruments to robotic systems. In competition, the da Vinci surgical robot is regarded as the market leader, and the company claims differentiation through its 90-degree multi-joint core patents.

After acquiring technology assets from FlexDex Surgical, the company says its intellectual property holdings rose to 939 items.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩10.3B-₩8.4B−81.5%
2026Q2₩12.5B-₩12.2B−97.5%
2026Q3₩8.9B-₩10.4B−116.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩27.1B-₩26.5B-₩25.6B−97.7%−64.6%34.5%
2025₩51.2B-₩22.6B-₩22.9B−44.2%−12.6%11.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

LivsMed posted operating losses in both 2024 and 2025, with revenue growing and losses narrowing. Revenue rose 88.8% from KRW 27.1 billion in 2024 to KRW 51.2 billion in 2025, while the operating loss narrowed from KRW 26.5 billion to KRW 22.6 billion. The operating margin improved from -97.7% to -44.2%.

The net loss attributable to controlling shareholders narrowed from KRW 25.6 billion in 2024 to KRW 22.9 billion in 2025, and the net loss including non-controlling interests narrowed over the same period from KRW 25.6 billion to KRW 22.9 billion.

Operating cash flow worsened from -KRW 27.7 billion in 2024 to -KRW 34.7 billion in 2025. The company attributed the 2025 losses to investment costs for the STARK surgical robot, new product certifications and overseas market development for the ArtiSeal vascular closure device.

The debt ratio fell from 34.5% in 2024 to 11.6% in 2025. In 2026, revenue was KRW 10.3 billion in the first quarter with an operating loss of KRW 8.37 billion, and in the second quarter revenue rose to KRW 12.5 billion (up 21.9% from the prior quarter) while the operating loss widened to KRW 12.2 billion.

Third-quarter revenue was KRW 8.92 billion, down 28.7% from the prior quarter, and the operating loss narrowed to KRW 10.4 billion. The net loss attributable to controlling shareholders in the third quarter was KRW 15.5 billion, larger than the operating loss.

Based on the first-half 2026 figures reported by the press, the gross margin fell from 61.3% to 43.4%, and general and administrative R&D expenses rose 51.5%.

The company attributed the third-quarter revenue decline to the sell-through of the previous-generation product ahead of the ArtiSential PRO launch and to inventory adjustments in the distribution channel.

05

Industry analysis

The surgical instrument and surgical robot market in which LivsMed operates is expanding as laparoscopic surgery spreads and multi-joint instruments combine with robotic systems.

The company cites the rise in hospitals and surgeons using ArtiSential from the third quarter of 2023 to the third quarter of 2026 as evidence of demand. The number of hospitals rose about 1.8 times and the number of surgeons about 2.2 times over that period.

On the distribution side, the company signed a contract in April 2025 with HealthTrust, a major US group purchasing organization for medical devices, gaining access to a network of 1,800 hospitals and 2,500 ambulatory surgery centers.

In Japan, the company says it is raising market share on the back of securing national insurance reimbursement. A 2026 feature on promising bio companies cited Korea Investment & Securities' analysis that expanding the product lineup from one to four products would have a large effect.

In competition, LivsMed faces the da Vinci surgical robot, which is regarded as the market leader. The company claims its 90-degree multi-joint core patents will give it an exclusive position in advanced instruments and robots for decades, but this is the company's own assertion.

The company also states that STARK will popularize surgical robots at a reasonable price and take an untapped share of the market.

06

Outlook

The company set a 2026 annual target of KRW 150.8 billion in revenue and KRW 14.3 billion in operating profit. First-half 2026 revenue reached only about 15% of that target, and third-quarter revenue fell from the prior quarter.

Press reports say the key drivers of a performance rebound in the second half will be the expansion of US supply, the re-release of ArtiSeal and the STARK product approval. ArtiSeal, the high-grade instrument, is stabilizing its mass production, and the company is preparing the launch of ArtiSential PRO.

For STARK, the company plans to pursue Japanese and US approvals after Korean approval within the year. The land and buildings for Yongin AMF, the global production hub, were acquired in June 2026, and the new plant is planned to start operations in the second half of 2027.

However, the original owner of the plant site has argued that the sale contract is void and filed a provisional injunction, leaving a possibility of legal disputes. On the funding side, the company signed loan agreements with Woori Bank and Hana Bank totaling KRW 28.4 billion in July 2026 after a board resolution.

The company describes its spending on new product commercialization and production capacity as planned investment. The next points to confirm are the STARK approval result, whether revenue recovers after the ArtiSential PRO launch, and the start date of the Yongin plant.

07

Valuation

PER
—
PBR
5.6×
ROE
-12.6%
EPS
—
BPS
₩6,151
Dividend per share
₩0

LivsMed's price-to-earnings ratio cannot be calculated because the last four quarters have produced net losses. The combined net loss attributable to controlling shareholders for the four quarters of 2025 was KRW 22.9 billion. With no earnings base, the valuation rests more on asset and growth indicators.

The price-to-book ratio sits in a range that represents a large premium over net assets. Total equity at the end of 2025 was KRW 180.9 billion, all of it attributable to controlling shareholders.

However, the accumulated unappropriated deficit rose to KRW 312.8 billion by the end of June 2026, so capital headroom is gradually shrinking. The dividend yield is effectively negligible, so dividends do little to explain the share price level.

A comparison of multiples with listed peers in the biopharma sector would require earnings-based measures that become meaningful only after a return to profitability.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Rapid expansion in revenue scale

Revenue reached KRW 51.2 billion in 2025, up 88.8%, with domestic sales growing 94.9%. Hospitals using ArtiSential rose to 262 at the end of the third quarter of 2026 from the level in the third quarter of 2023, and cumulative surgeries exceed 350,000. The number of surgeons using the product rose to 695, broadening the adoption base.

Narrowing losses and margin improvement

The operating loss narrowed from KRW 26.5 billion in 2024 to KRW 22.6 billion in 2025, and the operating margin improved from -97.7% to -44.2%. The net loss attributable to controlling shareholders also narrowed, from KRW 25.6 billion to KRW 22.9 billion. The company attributes this improvement to rapid revenue growth and a shrinking loss ratio.

Expanding overseas distribution

The company has supply contracts with 72 countries and supplies products in 46 of them. Overseas sales in 2025 rose 49.3% to KRW 5.5 billion, and sales at overseas subsidiaries grew 52.8%.

The HealthTrust group purchasing contract in the US and national insurance reimbursement in Japan are cited as foundations for wider distribution.

09

Bear factors

Operating losses for three straight quarters

Operating losses were KRW 8.37 billion in the first quarter of 2026, KRW 12.2 billion in the second and KRW 10.4 billion in the third, three straight quarters of losses. The loss widened in the second quarter, and third-quarter revenue fell 28.7% from the prior quarter to KRW 8.92 billion. Press reports on the first half said revenue reached only about 15% of the company's target.

Cash outflows and rising borrowing

Cash and equivalents at the end of June 2026 were KRW 64.6 billion, down 50.9% from the end of 2025. Operating cash outflow in the first half was -KRW 30.6 billion, with the outflow larger than a year earlier by more than KRW 10 billion.

The company signed loan agreements totaling KRW 28.4 billion, and some observers say further fundraising may be unavoidable if losses continue.

Uncertain timing for new product commercialization

STARK applied for product approval on August 7, 2026, and commercialization can only begin after approval. The new Yongin plant is planned to start in the second half of 2027, and a provisional injunction from the original owner of the site leaves a legal dispute open. Receivables turnover runs about 270 days, which means a long collection period.

10

Risk factors

Regulatory approvals and product timing

STARK needs Korean approval first and then Japanese and US approvals in sequence, so any delay postpones robot revenue. The launch of ArtiSential PRO and the stabilization of ArtiSeal mass production are also schedule risks.

If the inventory adjustments the company described last longer than expected, quarterly revenue volatility could continue.

Funding and balance sheet

Declining cash, operating cash outflows and the KRW 28.4 billion loan agreements are linked. The accumulated unappropriated deficit rose to KRW 312.8 billion, which reduces capital headroom over time.

Receivables older than three months reached KRW 14.4 billion at the end of June 2026, more than double the year-end 2025 level, which adds collection risk.

Competition, patents and legal disputes

The da Vinci system holds a strong market position as the leading surgical robot, so the pace of adoption is a variable. The company emphasizes the exclusivity of its core patents, but press reports note costs tied to patent litigation. The dispute over the plant site could also affect operating timelines.

11

What to watch next

  1. After November 2026 (timing not set)

    The Korean product approval result for STARK. Japanese and US approvals and commercialization can move forward only after this step, so it is the starting point for robot revenue.

  2. After November 2026 (timing not set)

    The launch of ArtiSential PRO and the stabilization of ArtiSeal mass production. This is where to confirm whether the third-quarter revenue adjustment was temporary or is followed by a quarterly recovery.

  3. End of March 2027

    Filing of the 2026 annual business report. Full-year 2026 revenue, operating loss and operating cash flow will be fixed, showing how the first-to-third-quarter losses look on an annual basis.

  4. Mid-May 2027

    The Q1 2027 quarterly report. This is the point to check how revenue and the operating loss compare with the first quarter of 2026, when revenue was KRW 10.3 billion and the operating loss was KRW 8.37 billion.

  5. Second half of 2027

    Start of operations at the new Yongin AMF plant. The production capacity expansion should be watched alongside the progress of the provisional injunction over the plant site.

12

Overall view

LivsMed showed both growth and narrowing losses, with 2025 revenue of KRW 51.2 billion, up 88.8%, and the operating margin improving from -97.7% to -44.2%.

On the other side, operating losses continued for three straight quarters from the first to the third quarter of 2026, and third-quarter revenue fell 28.7% from the prior quarter to KRW 8.92 billion. The gross margin in the first half also declined from 61.3% to 43.4%.

Cash fell 50.9% from the start of the year to the end of June 2026, and loan agreements totaling KRW 28.4 billion have added funding capacity. Strengths include wider hospital and surgeon adoption, supply contracts with 72 countries and the STARK approval application.

Weaknesses include continued losses, first-half revenue well below target and rising borrowing. These factors should be weighed equally, and the next points to confirm are the STARK approval result and first-quarter 2027 results. This report is provided for information only and does not state an investment opinion, rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. newstopkorea.com
  2. m.news.nate.com
  3. marvellab.maxnmarvel.com
  4. bloter.net
  5. news.nate.com
  6. view.asiae.co.kr
  7. pharm.edaily.co.kr
  8. rapportian.com
  9. bloter.net
  10. m.thinkpool.com
  11. globenewswire.com
  12. thebell.co.kr
  13. m.thebell.co.kr
  14. globenewswire.com
  15. ir.revmed.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis